Eric Weisblum

Biotech psychedelics researcher and developer Silo Pharma Inc. (OTCQB: SILO) announced its topically-administered proprietary ketamine obtained a positive outcome in a recent preclinical study. The trial has then proven the combination of Silo’s ketamine together with Zylo’s delivery...